Provider review
PeptidesRx Review: It Names Its Pharmacy, Then Says That Pharmacy Cannot Make This
PeptidesRx does the hardest disclosure in this category and contradicts it two clicks away. Its FAQ names the pharmacy — F&F Pharmacies Inc dba Jungle Jim’s Pharmacy, in Fairfield, Ohio — and the medical group. Almost nobody does that. The same paragraph then says the pharmacy "cannot dispense sterile compounds", while every product page claims an "FDA-registered 503B pharmacy".
Correction, August 2026
This review previously said: “So the peptides that would make this a peptide company — BPC-157, TB-500, CJC-1295, epitalon, MOTS-C — are advertised on an indexed page, are not purchasable, and are reachable only through a site-wide button that 404s.”
That was wrong. That was true of the PACKAGES on 9 August and is still true of them: /subscription-packages/ is still a 404 and the four package SKUs on /home-new/ are still marked not buyable. What changed is that the substances inside those packages have gone on sale as individual products. Reading the package SKUs and concluding the ingredients were unavailable was a reasonable inference in August and is a wrong one now, which is why this review re-derives a catalog from the store API rather than from a landing page.
It now says: Re-checked 2026-08-26. The store API returns thirty-eight products rather than twenty-six, and BPC-157 ($249), CJC-1295/Ipamorelin ($289), Epithalon ($299), MOTS-C ($309) and Tesamorelin ($259) are each purchasable, each with a live product page and an Add to Cart control. Four of those five are on FDA's published page of bulk substances that may present significant safety risks. The GLP-1s have moved the other way and are now the products the cart will not take. Every other finding on this page was re-derived from the raw HTML of six product pages and stands unchanged — including the 503B sentence, the BPC-157 typo on the Lipo-B page, the four permanent "Passed" rows, and zero occurrences of "certificate of analysis" anywhere on the site.
PeptidesRx gets closer to the disclosure this site keeps asking for than most of the companies reviewed here, and then breaks it in the same paragraph. It publishes the pharmacy's legal name, trading name, street address and phone number, and it publishes the medical group's name and address — two facts that let a reader check the chain instead of trusting an adjective. Then it says the pharmacy cannot dispense sterile compounds, sells a catalog of sterile injectables, and stamps "filled with USP-grade [product] at an FDA-registered 503B pharmacy" onto every listing, naming a company FDA's outsourcing-facility register does not contain. Two of those sentences name the wrong drug. Fifteen tell a semaglutide buyer to expect "smoother energy and focus within 7–10 days". The quality panel says "Passed" four times on every product with no lot and no document behind it, and the site-wide button offering monthly plans leads to a page that doesn't exist. This review carries no outbound link — not because of any rule about research chemicals, but because a page cannot route a reader to a checkout whose own operator's account of who makes the medicine does not agree with itself.
Worth trusting if
- You want the pharmacy and the medical group named with street addresses, which almost nobody in this category publishes
- You want the pharmacy's licensure limits stated by state rather than a blanket all-fifty claim
- You want a published price on every listing with no membership or subscription attached
Be skeptical if
- You want the two published answers about who fills your prescription to agree with each other
- You want a certificate of analysis, because the phrase appears zero times across the whole site
- You would rather not buy a substance FDA has flagged as possibly presenting significant safety risks, five of which are now individually for sale here
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
This review carries no link to PeptidesRx. Our disclosure policy does not permit one here.
Provenance
What PeptidesRx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin Injection or Oral Capsules — $176 on the product page, matching the store catalog, re-read unchanged 2026-08-26. A comparison block lower on the same page quotes $279 for the at-home option; that figure is identical on every product page regardless of what the product costs.
- PT-141 (Bremelanotide) — $289, re-read unchanged 2026-08-26. A home injection kit is included on orders over $450, so the advertised price is not the checkout total for a single item.
- NAD+ (injection or nasal spray) — $189 for the base listing, re-read unchanged 2026-08-26; the product has multiple variants selectable on the page.
- Glutathione — $156 on the shop listing, re-read unchanged 2026-08-26.
- Semaglutide (injections, oral drops or dissolvable melts) — $199 on the shop listing. The catalog records this product as an "external" type — the WooCommerce class used for an item bought elsewhere rather than in this cart — and re-checking on 2026-08-26 it is still marked not purchasable, as are Semaglutide Oral and Tirzepatide at $263. Meanwhile the FDA-flagged peptides that were not buyable in August now are.
- BPC-157 Injection — $249, read off the product page and the store catalog together on 2026-08-26 and marked buyable in both. A home injection kit is included on orders over $450, and the comparison block on this page quotes the same $279 at-home figure that appears on every other product page.
- CJC-1295/Ipamorelin — $289, read off the product page and the store catalog together on 2026-08-26 — the same figure PT-141 carries, which is one of several prices repeated across unrelated molecules here.
- Epithalon — $299, read off the product page and the store catalog together on 2026-08-26.
- MOTS-C — $309, read off the product page and the store catalog together on 2026-08-26 — the highest single-peptide price here, and the same figure the MOTS-C/Tesamorelin blend carries.
- Tesamorelin — $259, read off the product page and the store catalog together on 2026-08-26 — the cheapest of the five peptides added since August, and the only one of them with a completed trial behind the molecule.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Molecules with human evidence
For the use they are sold for, out of 10 products reviewed here. The evidence belongs to the molecule, not to PeptidesRx.
5
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from PeptidesRx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin Injection or Oral CapsulesSermorelin · Compounded (503A)No trial supports this claim
“Sermorelin is a growth hormone–releasing peptide that stimulates the pituitary gland to naturally increase growth hormone production. This supports recovery, boosts metabolism, enhances energy, improves sleep quality, and promotes anti-aging benefits… Supports lean muscle tone and fat metabolism · Improves sleep quality and supports healthy aging.”
Read on the PeptidesRx site, August 2026
No trial for this use
What the trials show for Sermorelin
As of 9 August 2026, a PubMed search for sermorelin restricted to the randomized-controlled-trial publication type returned 19 records. The most recent was published in August 2005 and measured growth hormone stimulation in healthy young and elderly subjects. Reading the full set, every one measures growth hormone secretion, growth in children, the response to a diagnostic challenge, or the interaction of GHRH with another agent. None measures sleep quality, recovery, metabolism, muscle tone, fat metabolism or any aging outcome — the six things this product page sells. The randomized sermorelin literature stopped twenty-one years ago without touching any of them.
The first sentence is pharmacology and it is correct: sermorelin is a GHRH analog and it does prompt the pituitary to release growth hormone. Everything after the full stop is a list of outcomes, and the sermorelin randomized literature contains none of them. There is a second problem specific to this listing: it is sold as "Injection or Oral Capsules". No registered trial has tested an oral sermorelin capsule, and a nine-amino-acid peptide taken by mouth faces the digestive tract that oral peptide formulations are engineered at great expense to survive. The page also states that the vial is "filled with USP-grade Sermorelin Injection at an FDA-registered 503B pharmacy" — the one pharmacy this site names is not on FDA's outsourcing-facility register, and the site's own FAQ says it cannot dispense sterile compounds.3,4
PT-141 (Bremelanotide)Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“PT-141, also known as bremelanotide, is a synthetic peptide and libido booster that has gained significant attention for its role in addressing sexual dysfunction in men and women. PT-141 is a melanocortin receptor agonist, meaning it targets specific receptors in the brain to affect sexual desire and arousal. Available as injections or nasal spray… Supports libido in men and women.”
Read on the PeptidesRx site, August 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 — Phase 3, completed, n=723. RECONNECT. "Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder." Every participant was a premenopausal woman.
- NCT02338960 — Phase 3, completed, n=714. The companion RECONNECT trial, same design, same population. Together these two are the entire phase 3 evidence base for the molecule, and both are in women.
Half of this claim is well supported and the other half is contradicted by the approved label. Bremelanotide's two phase 3 trials randomized 723 and 714 premenopausal women with hypoactive sexual desire disorder — real evidence, and the reason the molecule has an FDA approval at all. The approved product is Vyleesi, and its label states, in consecutive sentences: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." A ClinicalTrials.gov search on 9 August 2026 for bremelanotide restricted to erectile dysfunction as a condition returned zero studies. PeptidesRx sells it to "men and women" for "sexual dysfunction". The mechanism sentence is fair; the population is half invented. The listing also offers a nasal spray, and no phase 3 trial of the approved molecule used an intranasal route.5,6,7
NAD+ (injection or nasal spray)Nicotinamide adenine dinucleotide (NAD+) · Compounded (503A)No trial supports this claim
“NAD+ (Nicotinamide Adenine Dinucleotide) supports cellular energy and recovery, helping improve energy levels, focus, and overall vitality… Supports cellular energy and mitochondrial function · Promotes healthy aging and DNA repair processes · Enhances focus, mental clarity, and cognitive performance · Supports recovery, detoxification, and sleep quality.”
Read on the PeptidesRx site, August 2026
No trial for this use
As of 9 August 2026, a PubMed search for "nicotinamide adenine dinucleotide" or "NAD+" in title or abstract, combined with an injected route (subcutaneous, injection or intravenous) and restricted to the randomized-controlled-trial publication type, returned 4 records. Only one of the four actually administers NAD+ by an injected route: a 2026 randomized placebo-controlled trial in heart failure caused by ischemic cardiomyopathy. The other three are a phase 1 SIRT1-activator trial, a hypertonic-saline heart-failure study, and a 2006 paper on ethanol elimination. No randomized trial measures energy, focus, cognitive performance, DNA repair, detoxification or sleep quality with injected NAD+ in healthy adults, and none tests a nasal spray at all.
NAD+ is the product this business appears to have been built around — the /disclaimer page is written entirely about NAD+, the terms of service devote a clause to "NAD+ Prescriptions", and the state-compliance clause reads "We do not sell or ship to states where NAD+ prescribing is prohibited" on a site now selling twenty-six products. What has not kept pace is the evidence. Four randomized trials mention injected NAD+ and only one gives it; that one is in ischemic heart failure. None of the six benefits listed on this page has been measured in a randomized trial of this molecule by this route, and the nasal-spray presentation has no registered trial in any indication. The page's own "When will I notice results?" answer — "smoother energy and focus within 7–10 days" — is the sentence that has been copied onto fourteen other product pages, including the two GLP-1 pages.8,9
GlutathioneGlutathione · Compounded (503A)No trial supports this claim
“Glutathione is a powerful antioxidant used to support liver detox and promote brighter, clearer-looking skin and improved energy… Every prescription is reviewed by a U.S.-licensed clinician, filled with USP-grade Glutathione at an FDA-registered 503B pharmacy, and third-party tested for potency and sterility before it ships.”
Read on the PeptidesRx site, August 2026
No trial for this use
What the trials show for Glutathione
As of 9 August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route (injection, intravenous or intramuscular) and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned 7 records. Not one tests injected glutathione on its own for skin appearance, liver detoxification or energy in healthy adults. The nearest is a 2025 dermatology trial of an injectable combination of sodium hyaluronate, vitamin C, tranexamic acid and glutathione for pigmentation — a four-ingredient mesotherapy cocktail, from which no conclusion about glutathione alone can be drawn. The remaining six are critical-care, oncology and vaccine studies in which glutathione is a measured variable rather than the treatment.
The biochemistry is right — glutathione is a tripeptide and a principal endogenous antioxidant — and "liver detox", "brighter skin" and "improved energy" are three clinical endpoints that the injected-glutathione randomized literature has not established. The claim to grade here is really the second sentence rather than the first: "filled with USP-grade Glutathione at an FDA-registered 503B pharmacy". The one pharmacy this site names, F&F Pharmacies Inc dba Jungle Jim's Pharmacy, does not appear on FDA's published register of outsourcing facilities, and the site's own FAQ states it "cannot dispense sterile compounds". Glutathione here is a sterile injectable.10
Semaglutide (injections, oral drops or dissolvable melts)Semaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide works by helping you feel full sooner, crave less, and avoid the spikes and crashes that lead to overeating. Choose from injections, oral drops, or dissolvable melts. Each option is designed to support steady fat loss, reduce hunger, and fit seamlessly into your routine without extremes… Best for: Weight loss · Appetite control · Reduced cravings · Balanced blood sugar · Long-term weight management.”
Read on the PeptidesRx site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Novo Nordisk. Once-weekly subcutaneous semaglutide 2.4 mg versus placebo in adults with overweight or obesity, 68 weeks. Mean weight change −14.9% against −2.4%. The trial drug was the approved finished product administered by injection; no compounded preparation, and no oral drop or dissolvable melt, has been through a registered trial.
The mechanism paragraph is a fair description of what a GLP-1 receptor agonist does, and the molecule has one of the largest obesity trials ever run behind it. Three things reach past that. First, the presentations: STEP 1 tested a subcutaneous injection of the approved product, and this listing also sells "oral drops" and "dissolvable melts", formats with no registered trial and no published bioavailability data of their own. Second, the page carries the site's stock answer — "Many members report smoother energy and focus within 7–10 days. Cellular benefits build over 4–6 weeks" — which is NAD+ copy, and which reads on a GLP-1 page as a promise the drug's trials never made. Third, nothing on the page explains why a copy of a commercially available approved drug is being compounded at all: an FDA drug-shortage database query on 9 August 2026 returned only "Semaglutide Tablet — To Be Discontinued" entries from Novo Nordisk, with no injection listed in shortage.11,12,13
BPC-157 InjectionBPC-157 (body protection compound 157) · Compounded (503A)No trial supports this claim
“BPC-157 (Body Protection Compound) is a regenerative peptide that accelerates healing and recovery of muscles, tendons, ligaments, and the digestive tract… Best for: Injury recovery · Joint and tendon healing · Gut repair (ulcers, IBS) · Inflammation reduction.”
Read on the PeptidesRx site, August 2026
No trial for this use
Searched two ways on 26 August 2026, and both searches were checked against a molecule that does have trials before either absence was written down. ClinicalTrials.gov holds exactly one completed study naming BPC-157 at any phase: NCT07752381, a single-group, unblinded, 40-participant study of a chewable gummy containing 500 micrograms of BPC-157 per serving, sponsored by the company that sells the gummy, with no phase assigned and no results posted. There is no registry record of any kind for injected BPC-157, which is the only form sold here. PubMed returns 216 papers with BPC-157 in the title or abstract and not one of them is tagged as a randomized controlled trial; of the 49 tagged as involving humans, the recent ones are review articles, orthopedic commentaries and analytical-chemistry methods for detecting the peptide in blood samples. The same registry query returns 91 completed studies for tirzepatide and the same PubMed query returns 133, so the searches work; an invented drug name returns nothing in either.
This is the widest gap on the site between what a sentence promises and what has been measured in a person. "Accelerates healing and recovery of muscles, tendons, ligaments, and the digestive tract" is four therapeutic claims in one line, and the human literature contains a randomized trial of none of them. What exists is a large animal and cell literature, a set of review articles built on it, and one 40-person single-arm study of a gummy — no control group, no blinding, no phase, no posted results, and run by the firm selling the gummy. That study also tested the peptide by mouth; this product is an injection, and swapping the route is the step the site takes without comment. FDA names BPC-157 on its published page of bulk substances that may present significant safety risks, so it has no USP monograph, is not a component of any approved drug, and is not on the 503A bulks list — which makes the page's own "filled with USP-grade BPC-157 Injectionat an FDA-registered 503B pharmacy" wrong on the standard as well as on the facility, and missing a space in the middle of the sentence describing what is in the vial.15,16,17
CJC-1295/IpamorelinCJC-1295 and ipamorelin · Compounded (503A)Claim reaches past the trials
“CJC-1295 / Ipamorelin is a growth hormone support blend that stimulates the body’s own natural GH production to promote lean muscle, faster recovery, deeper sleep, and improved body composition. A favorite for those focused on performance, anti-aging, and overall vitality. Available as injections only… Best for: Supports lean muscle growth and fat loss · Promotes faster recovery and tissue repair · Enhances deep sleep and sleep quality · Boosts energy, drive, and overall vitality · Supports healthy aging and skin quality.”
Read on the PeptidesRx site, August 2026
No trial for this use
Searched on 26 August 2026, separately for each half of the blend and again for the blend itself. ClinicalTrials.gov holds no completed study of CJC-1295 in any condition, and none of the combination. It holds two completed studies of ipamorelin, both phase 2 and both sponsored by Helsinn: NCT01280344, 320 participants, gastrointestinal dysmotility, and NCT00672074, 117 participants, post-operative ileus. Recovery of bowel function after surgery is the condition ipamorelin was actually developed for, and it is not on this product page. PubMed returns one randomized controlled trial of CJC-1295 — Teichman 2006, which measured growth hormone and IGF-I concentrations in healthy adults — and two of ipamorelin, one the post-operative ileus trial and one a 1999 pharmacokinetic modeling study in volunteers. Across all five records, not one measures lean muscle, fat loss, tissue repair, sleep quality, energy, aging or skin. The same searches return 91 completed registry studies and 133 randomized papers for tirzepatide, and nothing for an invented drug name.
Graded differently from BPC-157 and epithalon on this page, and the difference is worth stating because it is the only thing separating them. The first half of this sentence has been demonstrated in a randomized trial of the actual molecule: CJC-1295 does prolong growth hormone and IGF-I secretion in healthy adults, which is what Teichman 2006 set out to measure and what it found. So the mechanism is not invented. Everything after the comma is, in the sense that matters here — "lean muscle, faster recovery, deeper sleep, and improved body composition" are outcomes, and no trial of either component has measured any of them. Ipamorelin's own two randomized trials are about getting a bowel working again after surgery. Two further things a buyer should carry: the blend as sold has never been studied as a blend, and FDA names both CJC-1295 and ipamorelin acetate on its page of bulk substances that may present significant safety risks, which is why "USP-grade CJC-1295/Ipamorelin Injection" points at a standard that does not exist. This page also heads its own comparison block "Why AOD-9604 Injection?", naming a third peptide entirely.18,19,20
EpithalonEpithalon (epitalon) · Compounded (503A)No trial supports this claim
“Epithalon is a longevity peptide that supports the body’s natural regenerative processes, helping promote healthy aging, better sleep, and cellular repair. A cornerstone peptide for those focused on longevity and anti-aging. Available as injections only… Best for: Supports healthy aging and longevity · Promotes cellular repair and regeneration · Enhances deep, restful sleep · Supports antioxidant and telomere health · Promotes overall vitality and wellness.”
Read on the PeptidesRx site, August 2026
No trial for this use
This is the emptiest registry result on the site. Searched under both spellings on 26 August 2026, ClinicalTrials.gov holds no study of epithalon or epitalon at any status — not completed, not recruiting, not withdrawn, none. PubMed returns 116 papers using either spelling and not one is tagged as a randomized controlled trial. A single record carries a clinical-trial tag: Khavinson 2002, a report from a St Petersburg institute describing rats and then patients with degenerative retinal disease, uncontrolled and unblinded, on an outcome — retinitis pigmentosa — that appears nowhere on this product page. Nothing in the human literature measures sleep, cellular repair, telomere length or any aging endpoint with this peptide. The same registry query returns 91 completed studies for tirzepatide and the same PubMed query 133 randomized papers, so the searches are working; an invented drug name returns nothing.
"Supports antioxidant and telomere health" is the specific claim to take seriously, because it is the one that sounds measurable. Telomere length is measurable, and no registered trial has measured it after giving a person epithalon. Neither has any trial measured sleep, regeneration or longevity, which is unsurprising given that the registry contains no study of this peptide at any status under either spelling. What the word "longevity peptide" is doing on a purchase page, then, is carrying an entire evidence base by implication. FDA names epitalon on its page of bulk substances that may present significant safety risks; there is no USP monograph for it, so "filled with USP-grade Epithalon Injection" describes a grade that cannot be assigned. The page also answers "When will I notice results?" with "smoother energy and focus within 7–10 days" — the same sentence this site's NAD+ page uses, on a product sold for something else entirely.21,22
MOTS-CMOTS-c · Compounded (503A)No trial supports this claim
“MOTS-C is a mitochondrial-derived peptide that works at the cellular level to boost energy production, support healthy metabolism, and enhance physical performance. Popular with those seeking better endurance, metabolic balance, and reduced fatigue. Available as injections only… Best for: Boosts cellular energy and mitochondrial function · Supports healthy metabolism and fat balance · Enhances physical performance and endurance · Reduces fatigue and supports recovery · Promotes overall vitality and wellness.”
Read on the PeptidesRx site, August 2026
No trial for this use
Searched on 26 August 2026, and this one turns on the difference between a peptide being given and a peptide being counted. Searching ClinicalTrials.gov by intervention — the field that records what participants actually received — returns no completed study of MOTS-c. A looser full-text search returns one, NCT04013568, an exercise study in breast-cancer survivors in which MOTS-c is a blood measurement rather than a treatment. PubMed tells the same story more clearly: four papers on MOTS-c are tagged as randomized controlled trials, and all four measure circulating MOTS-c as a marker — of heat stress during calf immobilization, of metformin treatment in breast cancer, of aerobic and resistance exercise, and of acute endurance exercise. Nobody in any of them was given the peptide. FDA's own stated reason for listing MOTs-C among bulk substances that may present significant safety risks is that the agency "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration", and these searches find none either. The same searches return 91 completed studies and 133 randomized papers for tirzepatide, and nothing for an invented drug name.
The biology behind the first clause is genuine and interesting — MOTS-c is a peptide encoded in mitochondrial DNA, and it does rise in the blood after exercise, which is exactly what the four randomized papers that mention it were measuring. That is the opposite of the claim being made here. Those studies show the body producing more MOTS-c when a person trains; this page sells an injection on the premise that putting MOTS-c in will produce the training effect. No trial has tested that in a human, at any dose, by any route. FDA says the same thing in its own words on the bulk-substances page, which is why "filled with USP-grade MOTS-C Injection" is doubly odd: there is no monograph to grade against and no human exposure data behind the substance being graded. This is also the most expensive peptide in the catalog, and one of three pages whose comparison block is headed "Why AOD-9604 Injection?".23,24
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“Tesamorelin is a clinically studied growth hormone releasing peptide known for its powerful effect on reducing stubborn abdominal fat. It supports a leaner body composition, sharper mental clarity, and healthy metabolic function. Available as injections only… Best for: Targets stubborn abdominal and visceral fat · Supports a leaner, more defined body composition · Promotes healthy metabolism and energy · Enhances focus and mental clarity · Supports healthy aging and vitality.”
Read on the PeptidesRx site, August 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. Theratechnologies. Registered title: "A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation." Every participant had HIV.
- NCT00608023 — Phase 3, completed, n=263. The placebo-controlled extension of the same program, results posted. Same population, same condition: HIV subjects with excess abdominal fat accumulation.
"Clinically studied" is true, and tesamorelin is the only peptide on this page for which it is — which makes the population the whole question. The two phase 3 trials randomized 412 and 263 people, and every one of them had HIV with excess abdominal fat accumulation. The approved product built on those trials is Egrifta, and its label states the indication in one line — reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy — and then, under Limitations of Use, states the opposite of what this listing sells: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." This page sells it to anyone, for "stubborn abdominal fat" and "a leaner, more defined body composition", and never mentions HIV. On "sharper mental clarity" there is a trial and it is the wrong way round: a 2025 phase 2 study randomized 73 people with HIV and abdominal obesity to tesamorelin or standard care and concluded there was no clear cognitive benefit, while confirming the waist reduction. Two things in this product's favor, said plainly: tesamorelin is the active ingredient of an FDA-approved drug, so unlike the other four peptides added to this catalog it is not on FDA's safety-risk bulks page, and it is a substance a compounder has a lawful route to. The trials are real. The patients in them are not the patients being sold to.25,26,27,28
Dispensing chain
Who actually fills your prescription
- F&F Pharmacies Inc dba Jungle Jim's Pharmacy, 5484 Dixie Highway, Fairfield, OH 45014, (877) 858-3784
- Beluga Health, P.A. (the medical group, not a pharmacy) c/o Jonah Mink MD, 1321 Upland Dr., Suite 18399, Houston, TX 77043
Read the full account
PeptidesRx publishes more of its supply chain than almost anyone in this category, and then publishes a second statement that cannot stand beside the first. The FAQ page gives the pharmacy a name, a street address and a phone number: "F&F Pharmacies Inc dba Jungle Jim's Pharmacy is located at 5484 Dixie Highway Fairfield, OH 45014.. They can be contacted at (877) 858-3784. They are able to dispense medications and maintain a license in 44 US states." It also names the medical group: "Our clinical providers are Beluga Health c/o Jonah Mink MD… Beluga Health, P.A., a Florida professional corporation, has its office located at 1321 Upland Dr., Suite 18399, Houston, TX, 77043." Both are checkable, and publishing them is a real service to a patient. The next sentence is the problem: "Unfortunately, they cannot dispense sterile compounds and do not have a license in the following US states: CALIFORNIA, NEVADA, NEW JERSEY, NORTH CAROLINA, TEXAS, MASSACHUSETTS, MISSISSIPPI, NEW HAMPSHIRE, WEST VIRGINIA, and DELAWARE." Nearly everything in the catalog is a refrigerated sterile injectable. Set against that, every product page states the vial was "filled with USP-grade [product] at an FDA-registered 503B pharmacy, and third-party tested for potency and sterility before it ships" — and neither "F&F Pharmacies" nor "Jungle Jim" appears anywhere on FDA's published list of registered outsourcing facilities, checked on 9 August 2026 (the Ohio entries on that list are STAQ Pharma of Ohio in Columbus, Wedgewood Connect Ohio in Albany and RC Outsourcing in Lowellville — three different companies in three different cities). So either a second, unnamed facility fills the injectables, or the 503B sentence is not accurate; the site does not say which, and names no other pharmacy. Re-read on 26 August 2026 the FAQ paragraph is unchanged, word for word, including the sterile-compounds sentence and all ten states. One further disclosure, unusual and worth reading twice, appears in the terms and on every product page: "Products shipped directly from PeptidesRx will reflect the official PeptidesRx label." Some products, unspecified, ship from the company itself rather than from a pharmacy.
Read on the PeptidesRx site, August 2026.
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described program, not a document.
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Every product page carries a four-row panel headed "Quality tested", and every row on every page reads "Passed" — re-derived from the raw HTML of six product pages on 2026-08-26, six of six, because a rendered-text sweep of the same six URLs reported the panel missing and was wrong: the copy sits in collapsed accordions that never reach the rendered text. The rows are: a first row labeled "Customized plan — Passed — Confirmed every 3–6 months to stay within ± 10 % of the target strength", where a potency test plainly belongs and where the label has been overwritten; "Sterility test — Passed — Screened for bacteria, fungi, and other contaminants to meet USP 797 standards"; "Endotoxicity test — Passed — Checked to USP 85 limits"; and "pH test — Passed". No lot number, no date, no laboratory name and no document accompanies any of it — the string "certificate of analysis" occurs zero times across all 62 pages of the site, as does "COA". A standing "Passed" with no lot attached is a design element rather than a test result. The surrounding sentence adds a further oddity: medication is "independently verified in FDA- and DEA-registered labs" — DEA registration governs controlled substances, and nothing in this catalog is one. Beneath that sits the claim graded throughout this review, "filled with USP-grade [product] at an FDA-registered 503B pharmacy", asserted for products including BPC-157, MOTS-C and CJC-1295, none of which has a USP monograph to be graded against. And the global footer, on all 62 pages including every prescription injectable, carries the dietary-supplement formula: "These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease." A LegitScript seal is displayed and links to LegitScript's public lookup for peptidesinc.com; the seal image resolves under a genuine seal id while a fabricated id returns HTTP 403 from the same host, so the badge is reported as displayed rather than independently confirmed.
Read on the PeptidesRx site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Not published for the service. The only state list on the site belongs to the named pharmacy's licensure and is framed as an exclusion from its 44-state coverage
Read the full licensing claim
The terms of service say only: "You must be 18 years or older and reside in a state where our services are legally permitted. We do not service users in restricted jurisdictions," without naming one. The disclaimers page names none either, and is still written for a single product: "We do not sell or ship to states where NAD+ prescribing is prohibited." The one concrete list on the site is in the FAQ and belongs to the pharmacy rather than to the platform — Jungle Jim's is stated to hold a license in 44 states and to lack one in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia and Delaware. Those ten are recorded here because they are the only states the site names, not because PeptidesRx says it will not serve them. Product pages add "Certain peptide orders are available only in state-permitted locations. Availability will be confirmed during your intake review", which defers the answer past the point of payment. The "Select State" control that appears in the site-wide popup lists all fifty states and is a callback-request form, not an eligibility gate. Nothing here was verified against a state board.
Named as outside that footprint
Read on the PeptidesRx site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with PeptidesRx
We went through PeptidesRx’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Read the price first. Every product page publishes a figure at the top with no membership, subscription or account required to see it.
- Read the same page's safety sentence, which is where the contradiction lives: the vial is "filled with USP-grade [product] at an FDA-registered 503B pharmacy".
- Open the FAQ page for the other half. It names the pharmacy and the medical group with street addresses — and says the pharmacy cannot dispense sterile compounds.
- Choose a state from the Select State control in the page's own start panel, or call the specialist line.
- Press Start Online Visit or Add to Cart. The walk stopped before either.
- Every price is public before intake and none is a subscription. Sermorelin is $176, PT-141 $289, NAD+ $189, Glutathione $156, and the peptides that were unbuyable in August now price at $249 for BPC-157, $289 for CJC-1295/Ipamorelin, $299 for Epithalon and $309 for MOTS-C.
- A "$" figure on the page is not the checkout total: a home injection kit is included on orders over $450, and a comparison block on every product page quotes the same $279 at-home figure regardless of what that product costs.
- Charging is gated in the right direction — the site states "You're only charged if your prescription is approved" — and no membership or subscription is required to see or buy anything.
- The Select State control in the start panel lists all fifty states. It is a callback-request form, not an eligibility gate, and the product pages defer the real answer past payment: "Availability will be confirmed during your intake review."
- A specialist line is published with hours on the product page itself: (305) 842-9920, Monday to Saturday, 8am–8pm Eastern.
- The site-wide "monthly plans" button still points at /subscription-packages/, which still returned HTTP 404 on 26 August 2026.
- The brand's own domain, getpeptidesrx.com, still serves the same 1,498-byte "Temporarily closed" page — byte-identical for /catalog.html, checked again on 26 August 2026.
- The walk is partial in as many words: nothing was added to a cart, no online visit was started, no state was submitted, no account was created and nothing was bought. This review carries no outbound link and did not route anyone to a checkout.
PeptidesRx support
- Phone
- (305) 842-9920
- Hours
- Monday to Saturday, 8am–8pm Eastern
Assessment
What holds up, and what does not
- It names the pharmacy, with a street address and a phone number: "F&F Pharmacies Inc dba Jungle Jim's Pharmacy is located at 5484 Dixie Highway Fairfield, OH 45014… (877) 858-3784." Almost no telehealth brand publishes this.
- It names the medical group too: "Beluga Health, P.A., a Florida professional corporation", c/o Jonah Mink MD, with an address and a contact email — so the prescriber and the dispenser are separable questions a reader can pursue.
- It publishes the pharmacy's licensure limits by state rather than claiming blanket coverage, which is the opposite of the category's usual "all 50 states" boilerplate.
Show 4 more
- Prices are published on every listing and mirrored in an open store API, with no membership or subscription required — "No Subscription Required · No Hidden Fees" is accurate as far as the catalog goes.
- It states which label the vial will carry: "products dispensed through licensed 503A and 503B FDA-regulated compounding pharmacies will carry the dispensing pharmacy's label, not the PeptidesRx label." That is a genuinely useful thing to tell a patient before the box arrives.
- The intake is gated on payment in the right direction: "You're only charged if your prescription is approved."
- Cold-chain shipping is stated and priced in, and storage instructions appear on each product page rather than only in a leaflet.
- The named pharmacy cannot make most of what is sold. The FAQ states it "cannot dispense sterile compounds"; the catalog is largely refrigerated sterile injectables.
- Every product page claims the vial was filled "at an FDA-registered 503B pharmacy". Neither "F&F Pharmacies" nor "Jungle Jim" appears on FDA's published register of outsourcing facilities, and no second facility is named anywhere on the site.
- The Lipo-B and Lipo-C pages say the medication is "filled with USP-grade BPC-157 Injectionat an FDA-registered 503B pharmacy" — the wrong drug, and a missing space, in the sentence about what is in the vial.
Show 16 more
- Three pages now head their comparison block "Why AOD-9604 Injection?", naming a peptide the page is not selling: PT-141, CJC-1295/Ipamorelin and MOTS-C. The PT-141 page also reads "USP-grade PT-141 Injection Injection".
- All five newly buyable peptide pages answer "What if I miss a dose?" with "Do not double up; Sermorelin works cumulatively over time" — sermorelin instructions on the BPC-157, CJC-1295/Ipamorelin, Epithalon, MOTS-C and Tesamorelin pages, in the answer about dosing.
- Four of the five peptides added to the catalog since August have no completed human trial for what they are sold for, checked 26 August 2026. The fifth, tesamorelin, has two phase 3 trials in which every participant had HIV, and an approved label stating it is not indicated for weight loss management.
- Fifteen product pages, including Semaglutide and Tirzepatide, answer "When will I notice results?" with "smoother energy and focus within 7–10 days. Cellular benefits build over 4–6 weeks" — NAD+ copy on a weight-loss drug.
- The "Quality tested" panel reads "Passed" on every row of every product, with no lot, no date and no laboratory, and its first row is labeled "Customized plan" where the potency test should be.
- "Certificate of analysis" and "COA" occur zero times across all 62 pages.
- The site-wide "monthly plans" button, present in the global popup on every page, points at /subscription-packages/, which returns HTTP 404.
- The only page that lists those packages, /home-new/, is still published and sells nothing: the store's own data marks all four packages as not buyable, two of its six buttons lead to dead product pages, and two of its four prices disagree with the catalog.
- Those packages advertise BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, epitalon, Pinealon, MOTS-C and tesamorelin — and FDA names BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, epitalon and MOTs-C on its published page of bulk substances that may present significant safety risks.
- Since 9 August those substances have gone on sale individually. Re-checked 2026-08-26, BPC-157 at $249, CJC-1295/Ipamorelin at $289, Epithalon at $299 and MOTS-C at $309 are each buyable with their own product page and Add to Cart control — four substances on FDA's safety-risk bulks page, each sold as "USP-grade" when none has a USP monograph.
- The catalog has inverted. The GLP-1s with phase 3 trials behind them — Semaglutide, Semaglutide Oral and Tirzepatide at $263 — are now the products the cart will NOT take, marked external and not purchasable, while the FDA-flagged peptides are the ones it will.
- The global footer carries the dietary-supplement disclaimer — "These statements have not been evaluated by the Food and Drug Administration" — on every page, including prescription sterile injectables.
- The disclaimers page and the terms are still written for a one-product NAD+ business: "We do not sell or ship to states where NAD+ prescribing is prohibited", on a site selling twenty-six products.
- "Are they safe long-term? Studies suggest yes, especially when cycled properly" — an unqualified long-term safety claim, on an FAQ, for a category of compounded preparations with no long-term trials.
- "Do I need a prescription? Some peptides are regulated and may require a provider's prescription, depending on your location" — on a site whose name ends in Rx.
- The brand's own domain, getpeptidesrx.com, serves a byte-identical "Temporarily closed" page for every path including invented ones.
Verdict
The bottom line
Those two sentences cannot both be true of the same order. Neither named company holds the 503B registration the product pages claim, and the FAQ says the named pharmacy cannot dispense sterile compounds at all — so ask, in writing, which facility filled the specific vial being shipped to you.
The paragraph that gives, and the sentence that takes it back
Almost every review on this site ends up at the same missing fact: which pharmacy made the vial. PeptidesRx answers it, in public, on a page anyone can read:
Partner Pharmacy Information: F&F Pharmacies Inc dba Jungle Jim's Pharmacy is located at 5484 Dixie Highway Fairfield, OH 45014.. They can be contacted at (877) 858-3784. They are able to dispense medications and maintain a license in 44 US states.
And, two lines further down, the other half:
Our clinical providers are Beluga Health c/o Jonah Mink MD… Beluga Health, P.A., a Florida professional corporation, has its office located at 1321 Upland Dr., Suite 18399, Houston, TX, 77043
A named pharmacy with a street address, and a named medical practice with a street address. That is more than most of this category will ever tell you, and it should be said plainly before anything else.
Now the sentence that sits between those two, in the same paragraph:
Unfortunately, they cannot dispense sterile compounds and do not have a license in the following US states: CALIFORNIA, NEVADA, NEW JERSEY, NORTH CAROLINA, TEXAS, MASSACHUSETTS, MISSISSIPPI, NEW HAMPSHIRE, WEST VIRGINIA, and DELAWARE.
The catalog this pharmacy is named on is refrigerated sterile injectables: sermorelin, PT-141, NAD+, glutathione, B12, Lipo-B, Lipo-C, semaglutide, tirzepatide, high-dose vitamin C. Every product page carries the same storage line — "Keep refrigerated. Do not freeze."
Full analysis — 8 more sections"An FDA-registered 503B pharmacy" · The wrong drug, in the sentence about the drug · "Passed", four times, on everything · USP-grade what, exactly? · The packages that cannot be bought · What the evidence says about the rest of the shop · The disclaimers still belong to a different company · Why this page carries no link
"An FDA-registered 503B pharmacy"
Set against that, here is the sentence that appears, with only the product name swapped, on twenty-six pages:
Safety is our first priority. Every prescription is reviewed by a U.S.-licensed clinician, filled with USP-grade [product] at an FDA-registered 503B pharmacy, and third-party tested for potency and sterility before it ships.
Section 503B is a real designation and, unusually in this category, it is the right one to want: an outsourcing facility registers with FDA, is subject to FDA inspection and to current good manufacturing practice, and can make sterile products in batches. It is also a register you can read. 503A and 503B are not two words for the same thing, and the difference is exactly what a claim like this is trading on.
FDA publishes the list of registered outsourcing facilities. 1 On 9 August 2026 it was searched for "Jungle", "F&F" and "Fairfield". None of the three returns anything. The Ohio entries on that list are STAQ Pharma of Ohio in Columbus, Wedgewood Connect Ohio in Albany, and RC Outsourcing in Lowellville — three different companies, in three different cities, from the one PeptidesRx names.
So one of two things is true, and the site does not say which. Either the sterile injectables are filled by some other facility that PeptidesRx never names — in which case the disclosure that made this company look better than its competitors does not cover the products it sells — or the 503B sentence on twenty-six pages describes a status the named pharmacy does not hold.
That is the whole review, and everything below is a variation on it.
The wrong drug, in the sentence about the drug
If the 503B claim were the only defect it might be a wording problem. It is not, and what surrounds it is worse than a wording problem, because it is checkable in a browser in about a minute.
Template artifacts in production HTML, read 9 August 2026
| Page | What it says |
|---|---|
| Lipo-B (MIC+B12) | "filled with USP-grade BPC-157 Injectionat an FDA-registered 503B pharmacy" |
| Lipo-C | "filled with USP-grade BPC-157 Injectionat an FDA-registered 503B pharmacy" |
| PT-141 (Bremelanotide) | "USP-grade PT-141 Injection Injection"; comparison block headed "Why AOD-9604 Injection?" |
| NAD+ | "NAD+ Injectionat Home" |
| Semaglutide, Tirzepatide and 13 others | "When will I notice results? Many members report smoother energy and focus within 7–10 days. Cellular benefits build over 4–6 weeks" |
Two product pages tell a customer their vial was filled with BPC-157 when the product is a lipotropic injection. The PT-141 page runs its entire "why buy at home" comparison under the heading of a different peptide.
These are not typos in a blog post. They are in the safety paragraph, on the page where the purchase happens, describing what is in the syringe.
"Passed", four times, on everything
Each product page carries a panel headed Quality tested. It has four rows and, on every product, every row reads Passed.
- Customized plan — Passed — "Confirmed every 3–6 months to stay within ± 10 % of the target strength"
- Sterility test — Passed — "Screened for bacteria, fungi, and other contaminants to meet USP 797 standards"
- Endotoxicity test — Passed — "Checked to USP 85 limits to ensure zero harmful bacterial toxins"
- pH test — Passed — "Fine-tuned for a smooth, irritation-free injection"
Read the first row again. Its caption describes a potency test — ±10% of target strength, confirmed every three to six months — and its label says "Customized plan". The label has been overwritten with copy from somewhere else, which tells you how much attention the panel has had.
More to the point: no lot number, no date, no laboratory name and no document appears anywhere near it. Across all 62 pages of the site, the strings "certificate of analysis" and "COA" occur zero times. A permanent "Passed" attached to no lot is a graphic, not a result — and a certificate of analysis is a document, not a posture.
The sentence beside the panel adds one more thing worth noting: medication is "independently verified in FDA- and DEA-registered labs". DEA registration governs controlled substances. Nothing in this catalog is one.
USP-grade what, exactly?
The word doing the most work in that safety sentence is "USP-grade", and it appears attached to some substances that have no USP monograph to be graded against.
Scattered through the site — in the package copy on /home-new/ and in template strings leaking onto other product pages — the same construction appears for BPC-157, MOTS-C and CJC-1295.
Those three are not obscure. FDA names all three on its published page of bulk drug substances that may present significant safety risks, together with AOD-9604, epitalon, ipamorelin and thymosin beta-4 fragment (TB-500) — and every one of those seven appears in PeptidesRx's advertised monthly packages. 14 FDA's stated reason for MOTs-C is that the agency "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration."
A substance FDA has flagged for having no human exposure data does not have a United States Pharmacopeia monograph. "USP-grade" is being used the way "pharmaceutical grade" is used elsewhere in this industry: as a texture rather than a standard.
The monograph question is not decorative, either. Under section 503A a compounder may use a bulk drug substance only if it complies with a USP or NF monograph, or is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. 2 For BPC-157, MOTS-C, CJC-1295, epitalon, AOD-9604 and TB-500, none of the three doors is open — which is precisely why they are on the safety-risk page rather than the bulks list.
The packages that cannot be bought
Follow the monthly-plans button and the picture gets stranger.
That button sits in the global popup on every page of the site. It points at `peptidesinc.com/subscription-packages/`. On 9 August 2026 that URL returned HTTP 404.
The only page that does list the packages is `/home-new/`, which the site still publishes and search engines can still find. It advertises six monthly plans from $99 to $499, containing AOD-9604, BPC-157 capsules, NAD+, Pinealon, epitalon, GHK-Cu, glutathione, a BPC-157 + TB-500 blend, CJC-1295 + ipamorelin, tirzepatide and tesamorelin.
The six advertised packages, checked against the store API
| Package | Price on page | Store API | Buyable? |
|---|---|---|---|
| Essential Starter | $99/mo | $99.00 | is_purchasable false |
| General Wellness & Energy | $249/mo | $249.00 | is_purchasable false |
| Beauty & Anti-Aging Renewal | $379/mo | $389.00 | is_purchasable false |
| Strength & Recovery Builder | $389/mo | $249.00 | is_purchasable false |
| Men's Belly Fat & Vitality Reset | $399/mo | — | button 404s |
| Total Body Glow | $499/mo | — | button 404s |
So the peptides that would make this a peptide company — BPC-157, TB-500, CJC-1295, epitalon, MOTS-C — were advertised on an indexed page, were not purchasable, and were reachable only through a site-wide button that 404s. What could actually be bought was eighteen SKUs of sermorelin, PT-141, NAD+, glutathione, GHK-Cu cream, tretinoin, B12, lipotropics, methylene blue, ondansetron, hormone products, and compounded GLP-1s.
Re-checked 26 August 2026: they are for sale now
That last paragraph is written in the past tense because it no longer holds, and the way it stopped holding is worth the space.
`/subscription-packages/` still returns HTTP 404, and `/home-new/` still advertises the same six unbuyable packages. But the individual SKUs behind them have gone live. The store API now returns 38 products rather than 26, and these are each `is_purchasable: true`, each with a live product page and an Add to Cart control:
| Product | Price | On FDA's safety-risk bulks page? | |---|---|---| | BPC-157 | $249 | yes | | CJC-1295/Ipamorelin | $289 | yes, both | | Epithalon | $299 | yes | | MOTS-C | $309 | yes | | Tesamorelin | $259 | no | | DSIP | $359 | no |
Alongside them: Pinealon/PE22-28/Selank, Semax/Selank, MOTS-C/Tesamorelin, Tesamorelin/Ipamorelin, GHK-Cu + Epithalon, and four estradiol, progesterone and Biest preparations.
Every one of those product pages carries the same sentence as the rest — "filled with USP-grade [product] at an FDA-registered 503B pharmacy" — for substances that have no USP monograph to be graded against. The BPC-157 page still carries the "Injectionat" typo.
And the inversion is complete. It is now the GLP-1s that cannot be bought here: Semaglutide, Semaglutide Oral and Tirzepatide are all `type: external`, `is_purchasable: false`. The drugs with phase 3 trials behind them are the ones the cart will not take.
What the trials say about the five that went on sale
Those five are now graded above, one row each, and the pattern across them is sharp enough to state in a table before the detail. Every search below was run on 26 August 2026, and every one of them was run alongside a molecule known to return results — the same registry query finds 91 completed studies for tirzepatide, the same literature query finds 133 randomized papers — and alongside an invented drug name, which finds nothing. An absence only counts when the search that produced it can be shown to work.
Completed human trials of each peptide, for what it is sold for
| Sold here as | Completed registry studies | Randomized papers | What actually exists |
|---|---|---|---|
| BPC-157, $249 | 1 | 0 | A 40-person single-arm study of a gummy, run by the gummy's seller, no phase, no results posted. Nothing injected. 15 16 17 |
| CJC-1295/Ipamorelin, $289 | 2 (ipamorelin only) | 3 | Both ipamorelin trials are post-operative ileus. The one CJC-1295 trial measured hormone levels in healthy adults. 18 19 20 |
| Epithalon, $299 | 0 | 0 | No study at any status, under either spelling. One 2002 uncontrolled report, in retinitis pigmentosa. 21 22 |
| MOTS-C, $309 | 0 | 4 | All four randomized papers measure MOTS-c in blood. Nobody was given it. 23 24 |
| Tesamorelin, $259 | 14 | 21 | Two phase 3 trials, 412 and 263 people — every participant had HIV. 25 26 |
Three of those rows are the same shape: a peptide with real animal biology behind it, no human trial of the thing being sold, and a product page written as though the question were settled. The MOTS-C row is the one worth slowing down for, because the number 4 in that column looks like evidence and is not. All four randomized papers measured how much MOTS-c was already circulating in people after exercise, heat stress or metformin. They show the body making more of it when a person trains. This page sells an injection on the reverse premise. FDA's own stated reason for listing the substance is that it "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration", and searching for that data finds none either.
Tesamorelin is the exception and deserves to be marked as one. It is the only peptide added to this catalog with completed phase 3 trials behind the molecule, and the only one not on FDA's safety-risk page, because it is the active ingredient of an approved drug. The gap is who was in the trials. Both phase 3 studies enrolled people with HIV and excess abdominal fat, and the approved product's label — after naming that indication — adds a Limitation of Use that reads: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." 27 This page sells it for "stubborn abdominal fat" and "a leaner, more defined body composition", to anyone. On "sharper mental clarity" there is even a trial, and it points the other way: 73 people with HIV randomized to tesamorelin or standard care, no significant cognitive difference between the groups. 28
What is still not graded here: DSIP at $359, and the blends — MOTS-C/Tesamorelin, Tesamorelin/Ipamorelin, Pinealon/PE22-28/Selank, Semax/Selank and GHK-Cu + Epithalon. A blend has never been studied as a blend in any of these cases, which is its own finding, but it is not one this page has done the work to publish yet.
What the evidence says about the rest of the shop
Take the four peptides that were already on the shop in turn.
Sermorelin, $176, sold as an injection or oral capsules, for "recovery… metabolism… energy… sleep quality… anti-aging benefits". As of 9 August 2026 a PubMed search for sermorelin restricted to randomized controlled trials returns 19 records, the newest from August 2005. 3 4 Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures sleep, recovery, metabolism or body composition. And no registered trial has tested an oral sermorelin capsule at all — the secretagogue family rewards reading one molecule and one route at a time.
PT-141, $289, "addressing sexual dysfunction in men and women". This one has real evidence, and it is in one sex. Bremelanotide's two phase 3 trials, NCT02333071 and NCT02338960, randomized 723 and 714 premenopausal women with hypoactive sexual desire disorder. 5 6 The approved product built on them is Vyleesi, whose label says in consecutive sentences: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." 7 A registry search restricted to erectile dysfunction as a condition returns zero studies. The women's half of PeptidesRx's claim is well supported; the men's half is not.
NAD+, $189, injection or nasal spray, for energy, focus, DNA repair, detoxification and sleep. Four randomized trials mention injected NAD+ and only one administers it, in ischemic heart failure. 8 9 None of the six benefits on the page has been measured, and no registered trial tests a nasal spray in any indication.
Glutathione, $156, for "liver detox… brighter, clearer-looking skin and improved energy". Seven randomized records match injected glutathione with skin, detoxification, fatigue or energy; the nearest is a four-ingredient injectable cocktail for pigmentation from which nothing about glutathione alone follows. 10
The compounded semaglutide, at $199, is the one product with a major trial behind the molecule — STEP 1 randomized 1,961 adults and reported −14.9% against −2.4% on placebo. 11 12 But the listing also sells "oral drops" and "dissolvable melts", neither of which has a registered trial or published bioavailability, and the compounded preparation is not the trial drug in any presentation. Nothing on the page explains why a copy of a commercially available approved drug is being compounded: an FDA drug-shortage database query on 9 August 2026 returned only "Semaglutide Tablet — To Be Discontinued" entries, with no injection in shortage. 13
The disclaimers still belong to a different company
One last pattern, because it explains several of the others.
The /disclaimer page is titled "Disclaimers" and is written, in its entirety, about a single product:
NAD+ is prescribed by licensed medical providers in compliance with applicable laws… NAD+ should be used under the supervision of a licensed provider… We do not sell or ship to states where NAD+ prescribing is prohibited.
The terms of service devote clause 4 to "NAD+ Prescriptions". There are twenty-six products in the catalog.
And the global footer, on all 62 pages — including sermorelin, PT-141, glutathione and compounded semaglutide — carries the formula Congress wrote for dietary supplements:
These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease.
That sentence belongs on a bottle of magnesium. On a page selling a prescription sterile injectable it replaces the one disclosure a buyer most needs — that the preparation is compounded, is not FDA-approved, and has not been reviewed by FDA for safety, effectiveness or quality.
Why this page carries no link
This site links to providers it reviews, including ones it criticizes sharply. It is not doing so here, and the reason is narrow enough to state precisely.
Nothing in this catalog is research-use-only material, so the rule that would force this automatically does not apply. The judgment is about the one question this whole site exists to ask: who fills the prescription, under which regulatory section, and where are they licensed? PeptidesRx answers that question twice, on its own pages, and the two answers cannot both be true — a named pharmacy that "cannot dispense sterile compounds", and twenty-six pages of sterile injectables filled "at an FDA-registered 503B pharmacy" by a company FDA's register does not list. Two of those pages name a different drug entirely. The button offering monthly plans leads to a page that doesn't exist.
None of that is an allegation about the medicine. It is a statement about what can be verified, and right now the answer is: less than the site claims, and less than it claimed three months ago on a domain that is now a placeholder. If the pharmacy statement and the 503B claim are brought into agreement, this decision changes.
Questions
Frequently asked questions
Does PeptidesRx say which pharmacy fills its prescriptions?
Yes, and that is the best thing about it. The FAQ page reads: "Partner Pharmacy Information: F&F Pharmacies Inc dba Jungle Jim's Pharmacy is located at 5484 Dixie Highway Fairfield, OH 45014.. They can be contacted at (877) 858-3784. They are able to dispense medications and maintain a license in 44 US states." It also names the medical group — "Beluga Health, P.A., a Florida professional corporation", c/o Jonah Mink MD, at 1321 Upland Dr., Suite 18399, Houston, TX 77043. Publishing both halves of the chain with addresses is rare and genuinely useful. The difficulty is the sentence that follows the first one, which says the pharmacy "cannot dispense sterile compounds", on a site whose catalog is largely refrigerated sterile injectables.
Is the pharmacy really an FDA-registered 503B outsourcing facility?
Not on FDA's published register. Every product page states the medication was "filled with USP-grade [product] at an FDA-registered 503B pharmacy, and third-party tested for potency and sterility before it ships." FDA maintains a public list of registered outsourcing facilities; on 9 August 2026 it was searched for "Jungle", "F&F" and "Fairfield" and none of the three appears. The Ohio entries on that list are STAQ Pharma of Ohio in Columbus, Wedgewood Connect Ohio in Albany and RC Outsourcing in Lowellville — different companies in different cities. So either an unnamed second facility fills the sterile products, or the sentence on twenty-six pages does not describe the pharmacy the site names. This review takes no position on which; it reports that the site publishes both statements and reconciles neither.
Why does this review carry no link to the provider?
By hand, and for one reason. Nothing PeptidesRx sells is research-use-only material, so the rule that automatically strips a link does not apply here. The judgment is that the site cannot presently answer the question this whole site exists to ask — who fills the prescription and under which regulatory section — because its own two published answers contradict each other, and because the purchase path is broken in ways anyone can check: the site-wide "monthly plans" button returns HTTP 404, the page listing those packages sells four SKUs the store API marks as not purchasable, and two product pages state the wrong drug in the sentence describing what is in the vial. The review stands and the decision is reversible.
Are the peptides — BPC-157, CJC-1295, epitalon, MOTS-C — actually for sale?
Individually, yes, as of 26 August 2026 — which is a change from this review's first reading and is corrected at the top of the page. BPC-157 is $249, CJC-1295/Ipamorelin $289, Epithalon $299, MOTS-C $309 and Tesamorelin $259, each with its own product page and an Add to Cart control, each marked purchasable in the store's own data. FDA names BPC-157, CJC-1295, ipamorelin, epitalon and MOTs-C on its published page of bulk drug substances that may present significant safety risks, and every one of those pages nonetheless describes the vial as "filled with USP-grade [product] at an FDA-registered 503B pharmacy" — for substances that have no USP monograph to be graded against. The PACKAGES are a separate matter and are still broken: six monthly plans from $99 to $499 are advertised on /home-new/, four are marked not buyable, two link to dead product pages, and the site-wide button pointing at /subscription-packages/ still returns HTTP 404. All five of those peptide pages are now graded against the literature above, and the short version is that four of the five have no completed human trial of the thing being sold: the only registry record for BPC-157 is a 40-person study of a gummy, epithalon has no registered study at any status under either spelling, every randomized paper on MOTS-c measures it in blood rather than giving it, and the two completed ipamorelin trials are about recovering bowel function after surgery. Tesamorelin is the exception, with two phase 3 trials behind it — in people with HIV.
What can you actually buy from PeptidesRx?
More than when this review was written, and not the things you would expect. The store catalog held twenty-six products on 9 August 2026 and holds thirty-eight on 26 August. The peptides are now buyable individually — BPC-157 $249, CJC-1295/Ipamorelin $289, Epithalon $299, MOTS-C $309, Tesamorelin $259, DSIP $359, plus Pinealon/PE22-28/Selank, Semax/Selank and two tesamorelin blends — alongside Sermorelin $176, PT-141 $289, NAD+ $189, Glutathione $156, GHK-Cu cream, tretinoin, B12, lipotropics, methylene blue, ondansetron, high-dose vitamin C, two therapy bundles, a vial cooler and four estradiol, progesterone and Biest preparations. What you CANNOT buy in this cart is the GLP-1s: Semaglutide, Semaglutide Oral and Tirzepatide at $263 are all marked "external" and not purchasable. No membership or subscription is required, and the site states "You're only charged if your prescription is approved."
Does PeptidesRx publish a certificate of analysis?
No. Every product page shows a four-row "Quality tested" panel in which every row reads "Passed" — a potency-style row mislabeled "Customized plan", a sterility row citing USP 797, an endotoxicity row citing USP 85, and a pH row. No lot number, date or laboratory name appears anywhere near it, and across all 62 pages of the site the strings "certificate of analysis" and "COA" occur zero times. A standing "Passed" attached to no lot is a design element rather than a test result. The accompanying claim that medication is "independently verified in FDA- and DEA-registered labs" is also odd: DEA registration governs controlled substances, and nothing in this catalog is one.
Which states does PeptidesRx serve?
The site does not say. The terms state only that you must "reside in a state where our services are legally permitted" and that "We do not service users in restricted jurisdictions", without naming one; the disclaimers page names none either and is still written around a single product — "We do not sell or ship to states where NAD+ prescribing is prohibited." The one concrete list on the site belongs to the pharmacy: Jungle Jim's is stated to hold a license in 44 states and to lack one in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia and Delaware. Product pages defer the rest past checkout: "Certain peptide orders are available only in state-permitted locations. Availability will be confirmed during your intake review."
Has PeptidesRx received an FDA warning letter?
No. On 9 August 2026 we searched FDA's warning-letter index for "peptidesrx", "peptidesinc", "peptides rx", "jungle jims", "junglejims", "f&f pharmacies" and "beluga". Every search came back empty except "peptides rx", whose single result is a July 2021 letter to Biomedical Research Laboratories, LLC — a different company and a different product line. We know the search works, because the same search run the same way finds other companies' letters. One caveat: no warning letter is not an inspection record.
Why is getpeptidesrx.com showing a "temporarily closed" page?
The site does not explain, and the closure is total. On 9 August 2026 getpeptidesrx.com and www.getpeptidesrx.com each returned a 1,498-byte page reading "Temporarily closed — Our site is under construction. We'll be back soon. Questions? support@getpeptidesrx.com", and served the exact same page for its catalog, its FAQ, its terms and even a deliberately made-up address. Every path on the domain shows the same closed sign, with nothing behind it. The operating storefront is peptidesinc.com, whose page title is "PeptidesRx", whose favicon files are named cropped-Peptidesrx-Logo, and whose social accounts are instagram.com/peptidesrxinc and tiktok.com/@peptides_rx. That is how the two were connected here — brand marks and asset names, not the similarity of the words.
Does the site say peptides do not need a prescription?
One answer comes close. The FAQ asks "Do I need a prescription?" and answers: "Some peptides are regulated and may require a provider's prescription, depending on your location." Elsewhere the site is unambiguous that everything is prescribed after an intake reviewed by a clinician, which is the correct account, so the FAQ answer reads as legacy copy rather than an offer. Two other FAQ answers are worth flagging for the same reason: "Are they safe long-term? Studies suggest yes, especially when cycled properly and used under guidance" is an unqualified long-term safety claim with no study named, and "Are peptides natural? Yes. They are synthetic versions of peptides your body already makes" is untrue of several molecules in the advertised packages — CJC-1295 is a modified analog built for a longer half-life, and the body makes nothing like it.
Glossary
Key terms
Show definitions
- 503B outsourcing facility
- A compounder that registers with FDA under section 503B, is subject to FDA inspection and to current good manufacturing practice, and may produce sterile products in batches. Registration is not approval of any product, and the register is public — which is what makes a 503B claim checkable in a way a 503A claim is not.
- Sterile compounding
- Preparation of a medicine intended for injection or the eye, under conditions designed to exclude micro-organisms and particulates. It requires a cleanroom, validated processes and testing, and a pharmacy license that permits it. A pharmacy that "cannot dispense sterile compounds" cannot supply an injectable.
- USP monograph
- A public standard from the United States Pharmacopeia setting out what a substance must be and how to test it. "USP-grade" means measured against a monograph. Where no monograph exists — as for BPC-157, MOTS-C and CJC-1295 — the phrase has nothing to point at.
- Certificate of analysis
- A lot-specific laboratory report stating what was tested and what the results were. A row that permanently reads "Passed" with no lot number, no date and no laboratory is not one, and the phrase does not appear anywhere on this site.
- Dietary supplement disclaimer
- The sentence "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease," written by Congress for supplements. On a prescription compounded injectable it is the wrong instrument, and it displaces the compounded-drug disclosure a buyer actually needs.
Compare
Others selling what PeptidesRx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off PeptidesRx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 28 sources
- US Food and Drug Administration (2026). Registered Outsourcing Facilities — the published list of facilities registered as human drug compounding outsourcing facilities under section 503B of the FD&C Act. Searched 2026-08-09 for "Jungle", "F&F" and "Fairfield": no match. The Ohio entries are STAQ Pharma of Ohio, LLC (Columbus), Wedgewood Connect Ohio, LLC (Albany) and RC Outsourcing, LLC (Lowellville). fda.gov. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- US Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — a bulk substance may be used only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. Read 2026-08-09. fda.gov. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent published August 2005; every one measures growth hormone secretion, growth in children or the response to a diagnostic challenge, and none measures sleep, recovery, metabolism or body composition. Run 2026-08-09. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European Journal of Endocrinology 153(2):249-56 — the most recent randomised trial in the sermorelin literature. https://pubmed.ncbi.nlm.nih.gov/16061831/
- Palatin Technologies / AMAG Pharmaceuticals (2026). RECONNECT: Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02333071 — phase 3, completed, enrolment 723 actual. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT02333071
- Palatin Technologies / AMAG Pharmaceuticals (2026). RECONNECT companion trial: Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02338960 — phase 3, completed, enrolment 714 actual. A ClinicalTrials.gov search for bremelanotide restricted to condition "erectile dysfunction" returns 0 studies. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT02338960
- Cosette Pharmaceuticals, Inc. (2025). VYLEESI (bremelanotide) injection — prescribing information, section 1: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." Read 2026-08-09. DailyMed (US National Library of Medicine), SPL setid f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
- US National Library of Medicine (2026). PubMed search: ("nicotinamide adenine dinucleotide"[tiab] OR "NAD+"[tiab]) AND (subcutaneous[tiab] OR injection[tiab] OR intravenous[tiab]) AND randomized controlled trial[pt] — 4 records, only one of which administers NAD+ by an injected route. Run 2026-08-09. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28%22nicotinamide+adenine+dinucleotide%22%5Btiab%5D+OR+%22NAD%2B%22%5Btiab%5D%29+AND+%28subcutaneous%5Btiab%5D+OR+injection%5Btiab%5D+OR+intravenous%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Yu X, Xu J, Cao J, et al. (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. American Journal of Cardiovascular Drugs 26(1):97-106 — the only randomised trial administering NAD+ by an injected route. https://pubmed.ncbi.nlm.nih.gov/40954388/
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND (injection[tiab] OR intravenous[tiab] OR intramuscular[tiab]) AND (skin[tiab] OR detoxification[tiab] OR fatigue[tiab] OR energy[tiab]) AND randomized controlled trial[pt] — 7 records; none tests injected glutathione alone for skin appearance, detoxification or energy in healthy adults. Run 2026-08-09. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+%28injection%5Btiab%5D+OR+intravenous%5Btiab%5D+OR+intramuscular%5Btiab%5D%29+AND+%28skin%5Btiab%5D+OR+detoxification%5Btiab%5D+OR+fatigue%5Btiab%5D+OR+energy%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002 — mean body-weight change −14.9% versus −2.4% on placebo at week 68. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Novo Nordisk A/S (2026). STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity, NCT03548935 — phase 3, completed, enrolment 1,961 actual; the intervention was a once-weekly subcutaneous injection of the approved product. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT03548935
- US Food and Drug Administration (2026). FDA drug shortage database, openFDA endpoint, queried for generic_name "semaglutide" on 2026-08-09 — returns only Semaglutide Tablet entries from Novo Nordisk with status "To Be Discontinued"; no semaglutide injection presentation is listed as in shortage. api.fda.gov / FDA Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
- US Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — content current as of 04/22/2026; names BPC-157, thymosin beta-4 fragment (LKKTETQ, "also known as TB-500"), CJC-1295, ipamorelin acetate, AOD-9604, epitalon and MOTs-C, each with FDA's stated potential significant safety risk. Read 2026-08-09. fda.gov. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- US National Library of Medicine (2026). ClinicalTrials.gov v2 API, searched 2026-08-26 for BPC-157 under both spellings — 1 completed study by full-text search and 1 by intervention, in both cases the same record; no study of injected BPC-157 at any status. The identical query returns 91 completed studies for tirzepatide and 0 for an invented drug name. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/search?intr=BPC-157&aggFilters=status:com
- Parlay Wellness (2026). A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery, NCT07752381 — the only completed registry record naming BPC-157. Single-group assignment, no masking, no phase assigned, 40 participants, no results posted; the intervention is described as "Parlay Recover peptide gummies containing Body Protection Compound (BPC)-157 (500 µg per serving)", taken by mouth. Read 2026-08-26. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT07752381
- US National Library of Medicine (2026). PubMed search: ("BPC 157"[tiab] OR "BPC-157"[tiab]) — 216 records; the same search restricted to the randomized-controlled-trial publication type returns 0, and restricted to human studies returns 49, which are review articles, orthopedic commentary and analytical methods for detecting the peptide in blood. Run 2026-08-26. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28%22BPC+157%22%5Btiab%5D+OR+%22BPC-157%22%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 API, searched 2026-08-26 — CJC-1295: 0 completed studies in any condition, and 0 for the CJC-1295 plus ipamorelin combination. Ipamorelin: 2 completed studies, both phase 2 and both sponsored by Helsinn Therapeutics — NCT01280344, 320 participants, gastrointestinal dysmotility, and NCT00672074, 117 participants, post-operative ileus. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT01280344
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 91(3):799-805 — the only randomized controlled trial of CJC-1295 in PubMed; its outcomes are hormone concentrations in healthy adults, not muscle, fat, sleep or recovery. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Beck DE, Sweeney WB, McCarter MD (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease 29(12):1527-34 — one of only two randomized ipamorelin papers; the other is a 1999 pharmacokinetic modeling study in volunteers. https://pubmed.ncbi.nlm.nih.gov/25331030/
- US National Library of Medicine (2026). Epithalon searched 2026-08-26 under both spellings: ClinicalTrials.gov returns 0 studies at any status for either "epithalon" or "epitalon", and PubMed returns 116 records with either spelling in title or abstract of which 0 carry the randomized-controlled-trial publication type. The same registry query returns 91 completed studies for tirzepatide. ClinicalTrials.gov and PubMed (US National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/?term=%28epitalon%5Btiab%5D+OR+epithalon%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Khavinson V, Razumovsky M, Trofimova S, et al. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters 23(4):365-8 — the single epitalon record in PubMed carrying a clinical-trial publication type. Tagged Controlled Clinical Trial rather than Randomized Controlled Trial, and its outcome is degenerative retinal disease. https://pubmed.ncbi.nlm.nih.gov/12195242/
- US National Library of Medicine (2026). ClinicalTrials.gov v2 API, searched 2026-08-26 — MOTS-c returns 0 completed studies when searched by INTERVENTION, the field recording what participants received. A looser full-text search returns 1, NCT04013568, an exercise study in breast-cancer survivors in which MOTS-c is a blood measurement. The same intervention query returns 86 completed studies for tirzepatide and 332 for semaglutide. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/search?intr=MOTS-c&aggFilters=status:com
- US National Library of Medicine (2026). PubMed search: ("MOTS-c"[tiab] OR "MOTS c"[tiab]) AND randomized controlled trial[pt] — 4 records, run 2026-08-26. All four measure circulating MOTS-c as a marker rather than administering it: repeated heat stress during calf immobilization (Med Sci Sports Exerc 2025), metformin in breast cancer (Aging 2022), aerobic and resistance exercise in breast-cancer survivors (Sci Rep 2021) and acute endurance exercise (J Appl Physiol 2021). PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28%22MOTS-c%22%5Btiab%5D+OR+%22MOTS+c%22%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Theratechnologies (2026). A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation, NCT00123253 — phase 3, completed, enrolment 412 actual. Read 2026-08-26. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Falutz J, Potvin D, Mamputu JC, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes 53(3):311-22 — the published report of the tesamorelin phase 3 program; the placebo-controlled extension is registered as NCT00608023, 263 participants, results posted. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Theratechnologies Inc. (2026). EGRIFTA WR (tesamorelin) for injection — prescribing information, section 1: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." Limitations of Use: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." Approved under BLA 022505; read 2026-08-26. DailyMed (US National Library of Medicine), SPL setid 839334d3-8c1d-4c26-9036-2ab524a6ea75. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- Ellis RJ, Vaida F, Hu K, et al. (2025). Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. Journal of Infectious Diseases 231(5):1230-1238 — phase 2, 73 participants randomized 3:2 to tesamorelin or standard of care. Waist circumference fell more on tesamorelin; the between-group difference in neurocognitive performance was not significant, and the authors conclude "no clear benefit". https://pubmed.ncbi.nlm.nih.gov/39813152/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.